Practical recommendations for the prevention and correction of adverse reactions of sunitinib
https://doi.org/10.17650/1726-9776-2010-6-2-8-13
Abstract
At present Sunitinib is the drug of choice in the treatment of metastatic renal cell carcinoma. In some cases complications due to the use of the drug make it to be unreasonably discontinued, which potentially affects the results of therapy. The paper proposes practical recommendations for the prevention, timely detection, and correction of the adverse reactions of Sunitinib, which enables the treatment to be performed safely and in adequate doses.
Supporting agencies: sunitinib; metastatic renal cell carcinoma; complications; correction methods
About the Authors
S. L. Gutorov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
E. I. Borisova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
2. Figlin R.A., Hutson T.E., Tomczak P. et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008;26:5024.
3. NCCN Clinical practice guidelines in oncology™: kidney cancer, 2010. V. 2.
4. Barrios C.H., Hernandez-Barajas D.,Brown M.P. et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma (mRCC): preliminary results. Eur J Cancer Suppl 2009; 7(2):429; abstr 7122.
5. Алексеев Б.Я., Калпинский А.С. Тар-гетная терапия распространенного рака почки Сутентом: побочные эффекты и их коррекция. Онкоурология 2008;(3):1-8.
6. Thomas E., Hutson T.E., Figlin R.A. et al. Targeted therapies for metastatic renal cell carcinoma: An overview of toxicity and dosing strategies. Oncologist 2008;13:1084-96.
7. Kollmannsberger C., Soulieres D., Wong R. et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007;1(2 Suppl):41-54.
8. NCCN guidelines: cancer-related fatigue, 2008. V. 1.
9. Pfizer Inc. SUTENT® (sunitinib) summary of product characteristics, February 2009.
10. Wolter P., Stefan C., Decallonne B. et al. The clinical implications of sunitinibinduced hypothyroidism: a prospective evaluation. Br J Cancer 2008;99(3):448-54.
11. Ravaud A., Sire M. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. Ann Oncol 2009;20(5):966-7; author reply 967.
12. Lacouture M.E., Wu S., Robert C. et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008;13(9):1001-11.
13. Porta С., Szczylik С., Bracarda S. et al. Short-and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma. ASCO 2008; abstr 5114.
Review
For citations:
Gutorov S.L., Borisova E.I. Practical recommendations for the prevention and correction of adverse reactions of sunitinib. Cancer Urology. 2010;6(2):8-13. (In Russ.) https://doi.org/10.17650/1726-9776-2010-6-2-8-13
Views:
811
Email this article 